Modus Therapeutics Holding AB (99Z) Price & Analysis

0 Followers

99Z Stock Chart & Stats

€0.03

>-€0.01(-1.57%)

At close: Jan 08 4:00 PM EST

€0.03

>-€0.01(-1.57%)

Day’s Range― - ―

52-Week Range€0.01 - €0.33

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€4.07M

Enterprise Value€30.08M

Total Cash (Recent Filing)€6.93M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding121,628,494

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Debt-free Balance SheetReported zero total debt for 2023–2025 reduces bankruptcy and interest-rate risk and preserves flexibility. For an R&D-intensive biotech, low leverage supports the ability to pursue clinical programs or partnerships without near-term interest burdens, a durable financial advantage.

Focused Clinical Pipeline (sickle Cell Disease)A clear, focused lead program targeting vaso-occlusive complications in sickle cell disease aligns with a significant unmet medical need. Precision-medicine positioning and a single clinical focus can improve trial design efficiency, partnership appeal, and long-term value capture if clinical outcomes are positive.

Lean Operating FootprintA very small headcount implies a low fixed-cost base and the ability to outsource costly trial operations. This lean model can extend runway per financing round and improve capital efficiency for the next 2–6 months, a durable operational strength for a pre-revenue developer.

Bears Say

Persistent And Rising Cash BurnConsistent negative operating and free cash flow, worsening to ~-SEK 18.1m in 2025, signals ongoing financing needs. For a clinical-stage biotech this increases dilution and refinancing risk, constraining strategic optionality and requiring external capital to sustain development programs.

No Revenue / Pre-revenue ProfileAbsence of revenue through 2025 means the company remains fully dependent on financing or partnerships. Without commercial products, profitability is distant and the firm's long-term viability hinges on clinical success or licensing deals, a fundamental business-model risk.

Equity Volatility And Negative ReturnsVolatile equity levels and strongly negative ROE reflect repeated financing and operating losses. This pattern points to dilution and recapitalization risk for shareholders and signals limited balance-sheet resilience if clinical or funding setbacks occur, a lasting structural weakness.

99Z FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.33 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is €4.07M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 53 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on May 26, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in DE:99Z

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.